U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16NO.Br
Molecular Weight 246.144
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDROPHONIUM BROMIDE

SMILES

CC[N+](C)(C)c1cccc(c1)[O-].Br

InChI

InChIKey=CAEPIUXAUPYIIJ-UHFFFAOYSA-N
InChI=1S/C10H15NO.BrH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2326
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula BrH
Molecular Weight 80.9115
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Originator

Curator's Comment:: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

4.92047991E11
Preventing
ENLON

Approved Use

Enlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

Launch Date

4.92047991E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
110 min
0.5 mg/kg single, intravenous
dose: 0.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
110 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
56.6 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
84.2 min
1 mg/kg single, intravenous
dose: 1 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ATROPINE
EDROPHONIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis.
1977
[A patient of chronic graft-versus-host disease presenting simultaneously with polymyositis and myasthenia gravis].
2001 Aug
Laryngeal myasthenia gravis: report of 40 cases.
2001 Mar
[Giant-cell myocarditis without a symptom of heart failure seen in a patient with myasthenia gravis and concurrent Hashimoto's disease].
2001 Nov
Respiratory failure due to vocal cord paresis in myasthenia gravis.
2002
Clinical, electrophysiological and immunological remissions after thymectomy in myasthenia gravis.
2002 Apr
A safe and noninvasive test for vagal integrity revisited.
2002 Aug
Autosomal recessive limb girdle myasthenia in two sisters.
2002 Dec
[Seronegative myasthenia gravis].
2002 Jan
[Myasthenia gravis].
2002 Jan 1
[Ocular myasthenic syndrome and systemic lupus erythematosus].
2002 Jul
[Thymectomy in juvenile myasthenia gravis].
2002 Jul 16-31
[What to do in case of acquired ptosis].
2002 Mar
Respiratory chain complex-I defect mimicking myasthenia.
2002 Mar
The effect of edrophonium on autonomic outflow.
2002 Mar
A comparison of the chronotropic and dromotropic actions between adenosine triphosphate and edrophonium in patients undergoing coronary artery bypass graft surgery.
2002 Oct
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
2003
Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase.
2003 Apr
[Comparison between idiopathic achalasia and achalasia caused by Chagas' disease: a review on the publications about the subject].
2003 Apr-Jun
[Blepharospasm in a patient with thymoma and positive anti-acetylcholine receptor antibody].
2003 Aug
Ocular myasthenia gravis associated with euthyroid ophthalmopathy.
2003 Dec
Natural monomeric form of fetal bovine serum acetylcholinesterase lacks the C-terminal tetramerization domain.
2003 Dec 30
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
2003 Feb
Esophageal manometry in patients with clinical symptoms mimicking esophageal origin: a hospital-based ten-year experience.
2003 Jan
Simplified tilt table test protocol with continuous upright position during medication administration and no hydration.
2003 Jan
Clinical profile of myasthenia gravis in the Sultanate of Oman.
2003 Jul
Endplate dysfunction causing respiratory failure in a patient with prior paralytic poliomyelitis.
2003 Mar
Utility of ambulatory 24-hour esophageal pH and motility monitoring in noncardiac chest pain: report of 90 patients and review of the literature.
2003 May
Assessment of esophageal function in patients with myasthenia gravis.
2003 May
Facile synthesis of [11C]edrophonium and its analogues as new potential PET imaging agents for heart acetylcholinesterase.
2003 May 19
Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium.
2003 Nov
Interactions of edrophonium with neostigmine in the rat trachea.
2003 Oct
Cage amines as the stopper inhibitors of cholinesterases.
2003 Sep 1
Myasthenia gravis in childhood.
2004
Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
2004 Apr 13
Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy.
2004 Jan
Persistent diplopia after retrobulbar anesthesia.
2004 Jun
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.
2004 Mar
Nitric oxide and cardiac muscarinic control in humans.
2004 May
A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor.
2004 Oct
Evaluation of mechanisms of azinphos-methyl resistance in the codling moth Cydia pomonella (L.).
2004 Oct
Painful sweating.
2004 Oct 26
Pupil-sparing, painless compression of the oculomotor nerve by expanding basilar artery aneurysm: a case of ocular pseudomyasthenia.
2004 Sep
Ocular myasthenia gravis.
2004 Sep
'Dropped head sign' in myasthenia gravis.
2004 Sep
Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience.
2004 Sep 11
Does this patient have myasthenia gravis?
2005 Apr 20
Postinfectious myasthenia gravis: report of two children.
2005 May
Clinical utility of videofluorography with concomitant Tensilon administration in the diagnosis of bulbar myasthenia gravis.
2005 May
MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence.
2005 May
Patents

Sample Use Guides

In Vivo Use Guide
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8 Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated. Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions. For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:13:38 UTC 2021
Edited
by admin
on Sat Jun 26 15:13:38 UTC 2021
Record UNII
KX008093VW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EDROPHONIUM BROMIDE
MI  
Common Name English
TENSILON BROMIDE
Common Name English
BENZENAMINIUM, N-ETHYL-3-HYDROXY-N,N-DIMETHYL-, BROMIDE (1:1)
Systematic Name English
EDROPHONIUM BROMIDE [MI]
Common Name English
EDROPHONE BROMIDE
Common Name English
Code System Code Type Description
PUBCHEM
9336
Created by admin on Sat Jun 26 15:13:38 UTC 2021 , Edited by admin on Sat Jun 26 15:13:38 UTC 2021
PRIMARY
MERCK INDEX
M4834
Created by admin on Sat Jun 26 15:13:38 UTC 2021 , Edited by admin on Sat Jun 26 15:13:38 UTC 2021
PRIMARY Merck Index
DRUG BANK
DBSALT002779
Created by admin on Sat Jun 26 15:13:38 UTC 2021 , Edited by admin on Sat Jun 26 15:13:38 UTC 2021
PRIMARY
CAS
302-83-0
Created by admin on Sat Jun 26 15:13:38 UTC 2021 , Edited by admin on Sat Jun 26 15:13:38 UTC 2021
PRIMARY
FDA UNII
KX008093VW
Created by admin on Sat Jun 26 15:13:38 UTC 2021 , Edited by admin on Sat Jun 26 15:13:38 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY